Driving Innovation in Rare Blood Disorders: Jeff Schaffnit’s ASH 2025 Perspective
Jeff Schaffnit, General Manager and Head of Rare Blood Disorders at Sanofi, shared on LinkedIn:
”As I close the chapter on ASH2025, I’m energized by the conversations happening across the hematology community.
Being on the ground at conferences like ASH is so important for our work in rare blood disorders.
It’s where we connect with the researchers advancing the science, the clinicians treating patients every day, and the advocates representing the communities we serve – a convergence of those who have a real stake in the research, the data, and the outcomes.
The breadth of scientific innovation presented this year was impressive.
I heard a lot about the potential of multi-immune modulation as an approach to rare autoimmune conditions like Immune Thrombocytopenia (ITP), warm Autoimmune Hemolytic Anemia (wAIHA), and Sickle Cell Disease (SCD).
While hemophilia remains core to our mission, I’ve enjoyed expanding our scientific discussions with healthcare providers who manage patients with Complex Immune Dysregulation (CID) conditions.
There’s clearly significant room for improvement for these patients who often have no treatments approved specifically for their condition.
These face-to-face conversations remind us why we do what we do.
A red thread throughout all my discussions was how our work translates to real impact in patients’ daily lives.
Hearing directly from the hematology community about the challenges they face, the progress being made, and the work still ahead helps inform our path forward.
What were some of your key learnings from the meeting?”
Stay updated with Hemostasis Today.
-
Mar 10, 2026, 14:33Eugene Tang: A Look at What’s Happening in Life After Stroke Research Across Europe at ELASF 2026
-
Mar 10, 2026, 14:25Ahd Elmahi: Complex Case of Catecholamine-Induced Multiorgan Failure and Arterial Thrombosis in Community-Acquired Pneumonia
-
Mar 10, 2026, 13:36Nirupama Yechoor: How Survivors of Stroke Define Spiritual Wellbeing in Recovery
-
Mar 10, 2026, 13:17Jeannie Devereaux: A Novel Technique for Precise High-Dose PRP Injection in Hip Labral Tear
-
Mar 10, 2026, 13:13Wolfgang Miesbach: Highlighting a Critical and Overlooked Dimension of Rare Bleeding Disorders in Women at EAHAD 2026
-
Mar 10, 2026, 13:08Michael Ertl: Honoured To Be Elected Fellow of the European Stroke Organisation
-
Mar 10, 2026, 13:00Nita Radhakrishnan: Benchmarking Hemophilia Care Across Global Income Settings Using Data from India
-
Mar 10, 2026, 12:59Hisam Siddiqi: Night Sweats Are Not Always a Hematological Plot Twist
-
Mar 10, 2026, 12:54Tzu-Fei Wang: Reassuring Real-World Data for Clinicians to Guide Anticoagulation in Prostate Cancer